Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 55-62

  Baumhäkel, Magnus ^a   Custodis, Florian ^a   Schlimmer, Nils ^a   Laufs, Ulrich ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Endothelial function; Erectile dysfunction; Heart rate; Ivabradine

Indexed keywords

APOLIPOPROTEIN E; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IVABRADINE; LIPID PEROXIDASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFECT; ERECTILE DYSFUNCTION; FEMALE; HEART RATE; KNOCKOUT MOUSE; LIPID DIET; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BENZAZEPINES; BLOOD PRESSURE; CHOLESTEROL, DIETARY; COLLAGEN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROSIS; HEART RATE; IMPOTENCE, VASCULOGENIC; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PENILE ERECTION; PENIS; SUPEROXIDES; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 77956229711     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.03.002     Document Type: Article

References (29)

1. Bohm M., Baumhakel M., Probstfield J.L., et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomised AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). American Heart Journal 2007, 154:94-101.
2. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. The Journal of Urology 1994, 151:54-61.
3. Solomon H., Man J.W., Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003, 89:251-253.
4. Baumhakel M., Bohm M. Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. International Journal of Clinical Practice 2007, 61:361-366.
5. Kirby M., Jackson G., Betteridge J., Friedli K. Is erectile dysfunction a marker for cardiovascular disease?. International Journal of Clinical Practice 2001, 55:614-618.
6. Thompson I.M., Tangen C.M., Goodman P.J., et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005, 294:2996-3002.
7. Kannel W.B., Kannel C., Paffenbarger R.S., Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. American Heart Journal 1987, 113:1489-1494.
8. Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. European Heart Journal 2005, 26:967-974.
9. Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:807-816.
10. Skantze H.B., Kaplan J., Pettersson K., et al. Psychosocial stress causes endothelial injury in cynomolgus monkeys via beta 1-adrenoceptor activation. Atherosclerosis 1998, 136:153-161.
11. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Current Medical Research and Opinion 2005, 21:1115-1122.
12. Colin P., Ghaleh B., Monnet X., et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. American Journal of Physiology 2003, 284:H676-H682.
13. Custodis F., Baumhakel M., Schlimmer N., et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:2377-2387.
14. Xie D, Odronic S.I., Wu F., et al. A mouse model of hypercholesterolemia-induced erectile dysfunction. The Journal of Sexual Medicine 2007, 4:898-907.
15. Behr-Roussel D., Darblade B., Oudot A., et al. Erectile dysfunction in hypercholesterolemic atherosclerotic apolipoprotein E knockout mice. The Journal of Sexual Medicine 2006, 3:596-603.
16. Baumhaekel M., Schlimmer N., Buyukafsar K., Arikan O., Boehm M. Nebivolol, but not Metoprolol improves endothelial function of the corpus cavernosum in ApoE-knockout-mice. The Journal of Pharmacology and Experimental Therapeutics 2008.
17. Buyukafsar K., Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. European Journal of Pharmacology 2003, 472:235-238.
18. Baumhakel M., Custodis F., Schlimmer N., Laufs U., Bohm M. Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. The Journal of Pharmacology and Experimental Therapeutics 2008, 327:692-698.
19. Laufs U., Wassmann S., Czech T., et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology 2005, 25:809-814.
20. Yavuzgil O, Altay B., Zoghi M., et al. Endothelial function in patients with vasculogenic erectile dysfunction. International Journal of Cardiology 2005, 103:19-26.
21. Feldman H.A., Johannes C.B., Derby C.A., et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Preventive Medicine 2000, 30:328-338.
22. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. The Journal of Clinical Investigation 1997, 100:2153-2157.
23. Beere P.A., Glagov S., Zarins C.K. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984, 226:180-182. New York, N.Y.
24. Reil J.C., Bohm M. The role of heart rate in the development of cardiovascular disease. Clinical Research in Cardiology 2007, 96:585-592.
25. Drouin A., Gendron M.E., Thorin E., et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. British Journal of Pharmacology 2008, 154:749-757.
26. Reil J.C., Bohm M. BEAUTIFUL results-the slower, the better?. Lancet 2008, 372:779-780.
27. Baumhakel M., Schlimmer N., Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. International Journal of Impotence Research 2008, 20:493-500.
28. Bassiouny H.S., Zarins C.K., Kadowaki M.H., Glagov S. Hemodynamic stress and experimental aortoiliac atherosclerosis. Journal of Vascular Surgery 1994, 19:426-434.
29. Burnett A.L., Musicki B., Jin L., Bivalacqua T.J. Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opinion on Therapeutic Targets 2006, 10:445-457.